## ΙΚΚβ-ΙΝ-3

Cat. No.: Molecular Formula: Molecular Weight: Target: Pathway: Storage:	HY-163412 C <sub>18</sub> H <sub>27</sub> NO <sub>4</sub> 321.41 ΙΚΚ NF-κΒ Please store the product under the recommended conditions in the Certificate of Analysis.	
---	---	--

BIOLOGICAL ACTIVITY				
Description	IKKβ-IN-3 (Compound hit4) is a IKKβ inhibitor with an IC <sub>50</sub> value of 30.4 nM. IKKβ is a key enzyme in the NF-κB signaling pathway and is involved in the development of many diseases. IKKβ-IN-3 can be used in the study of CAF-induced arthritis <sup>[1]</sup> .			
IC₅₀ & Target	ΙΚΚβ 30.4 nM (IC <sub>50</sub> )			
In Vivo	IKKβ-IN-3 (Compound hit4) (10, 30 mg/kg; 1 dose, 14 days) can reduce inflammation in complete Freund's adjuvant-induced arthriti (AIA) rat model <sup>[1]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.			
	Animal Model:	Adjuvant-induced arthritis (AIA) rat model $^{[1]}$		
	Dosage:	10 and 30 mg/kg		
	Administration:	gastric gavage (i.g.)		
	Result:	At 30 mg/kg, significantly reduced rat paw swelling, inflammatory cell infiltration and hyperemia of the synovium.		
	Animal Model:			
	Dosage:			
	Administration:			
	Result:			

## REFERENCES

[1]. Li L, et al. The discovery of a novel IKB kinase  $\beta$  inhibitor based on pharmacophore modeling, virtual screening and biological evaluation. Future Med Chem. 2024;16(6):531-544.

## Product Data Sheet



## Caution: Product has not been fully validated for medical applications. For research use only.

 Tel: 609-228-6898
 Fax: 609-228-5909
 E-mail: tech@MedChemExpress.com

 Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA